Abionyx Pharma S.A (ABNX) | Stock Overview & Key Data
Abionyx Pharma S.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €14.44 on May 25, 2015
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Abionyx Pharma S.A
ABNX
|
128.36M Small-cap | -8.55% | -18.48% | -12.03% | -26.26% | -28.90% | 120.00% | 121.71% | 123.44% | -65.29% | -76.80% | -76.80% |
|
Abivax SA
ABVX
|
7.61B Large-cap | -36.61% | -28.82% | -25.31% | -26.24% | -38.04% | 2,047.73% | 517.65% | 305.72% | 1,019.45% | 447.83% | 447.83% |
|
Nanobiotix
NANO
|
1.39B Large-cap | -12.69% | 13.65% | 14.38% | 69.14% | 58.63% | 827.52% | 612.13% | 134.60% | 81.06% | 449.03% | 449.03% |
| 108.28M Small-cap | 0.00% | 23.20% | 42.59% | 42.59% | 42.59% | 46.36% | 46.36% | 46.36% | 46.36% | 46.36% | 46.36% | |
|
Maat Pharma S.A.C.A
MAAT
|
99.87M Small-cap | 4.27% | -50.17% | -51.97% | -51.97% | -51.97% | -56.15% | -56.15% | -56.15% | -56.15% | -56.15% | -56.15% |
|
Adocia S.A
ADOC
|
90.92M Small-cap | -16.80% | -12.18% | -33.92% | -48.11% | -38.93% | 33.97% | 24.49% | -48.16% | -91.56% | -47.55% | -47.55% |
Ownership & Short Interest
Calculate Your Abionyx Pharma S.A Investment Returns
Long-Term Investment Performance Analysis
Abionyx Pharma S.A stock price in May 2016 was €8.24, A €1,000.00 lump sum investment in Abionyx Pharma S.A made 10 years ago would be worth approximately €337.38 today, representing a negative return of -66.26%. This translates to an annualized return (CAGR) of -10.29%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ABNX's 52-week high and low?
- In the last 52 weeks, Abionyx Pharma S.A reached a high of €5.29 (on October 28, 2025) and a low of €1.17 (on N/A).
- What is the market cap and P/E ratio for ABNX?
- Curious about Abionyx Pharma S.A's size and valuation? Its market capitalization stands at 128.36M. When it comes to valuation, the P/E ratio (trailing twelve months) is -22.75, and the forward P/E (looking ahead) is -12.29.
- Does ABNX pay dividends? If so, what's the yield?
- As for dividends, Abionyx Pharma S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Abionyx Pharma S.A's main competitors or similar companies to consider before investing?
When looking at Abionyx Pharma S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX7.61B Healthcare Biotechnology 2,047.73% 517.65% Nanobiotix
NANO1.39B Healthcare Biotechnology 827.52% 612.13% Innate Pharma S.A
IPH108.28M Healthcare Biotechnology 46.36% 46.36% Maat Pharma S.A.C.A
MAAT99.87M Healthcare Biotechnology -56.15% -56.15% Adocia S.A
ADOC90.92M Healthcare Biotechnology 33.97% 24.49% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Abionyx Pharma S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Abionyx Pharma S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -123.01%, the Debt to Equity ratio from the most recent quarter is 0.84, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ABNX?
- Looking at Abionyx Pharma S.A's growth, its revenue over the trailing twelve months (TTM) was €4M. Compared to the same quarter last year (YoY), quarterly revenue grew by -10.20%, and quarterly earnings saw a YoY growth of N/A.
- How much of ABNX stock is held by insiders and institutions?
- Wondering who owns Abionyx Pharma S.A stock? Company insiders (like executives and directors) hold about 35.56% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 4.48%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.